Salvinorin A: Difference between revisions

Line 10:

==Pharmacology==

Salvinorin A is a potent [[Opioid#Kappa_.28.CE.BA.29|κ-opioid]] receptor [[agonist]]. It does not have any effect on the 5-HT2A receptor, the receptor targeted by most [[psychedelic]] drugs, nor does it function as an NMDA receptor antagonist as most dissociatives do. Its unique structure lacks features commonly associated with opioid ligand binding, namely it doesn't contain a quaternary carbon atom linked to a tertiary amine group by two other carbon atoms. Unlike traditional opioid agonists, salvinorin A targets the [[Opioid#Kappa_.28.CE.BA.29|κ-opioid]] receptor rather than the [[Opioid#Mu_.28.CE.BC.29|μ-opioid]] receptor. Salvinorin A is currently being researched in relation to its properties as an anti-addiction drug, and several analogs with improved pharmacokinetic profiles have been shown to have anti-addictive effects as well.<ref>http://www.ncbi.nlm.nih.gov/pubmed/24484985</ref>

Salvinorin A is a potent [[Opioid#Kappa_.28.CE.BA.29|κ-opioid]] receptor [[agonist]]. It does not have any effect on the 5-HT2A receptor, the receptor targeted by most [[psychedelic]] drugs, nor does it function as an NMDA receptor antagonist as most dissociatives do. Its unique structure lacks features commonly associated with opioid ligand binding, namely it doesn't contain a quaternary carbon atom linked to a tertiary amine group by two other carbon atoms. Unlike traditional opioid agonists, salvinorin A targets the [[Opioid#Kappa_.28.CE.BA.29|κ-opioid]] receptor rather than the [[Opioid#Mu_.28.CE.BC.29|μ-opioid]] receptor. Salvinorin A is currently being researched in relation to its properties as an anti-addiction drug, and several analogs with improved pharmacokinetic profiles have been shown to have anti-addictive effects as well.<ref>http://www.ncbi.nlm.nih.gov/pubmed/24484985</ref> Salvinorin A also acts as a potent agonist at [[dopamine|D2]] receptors<ref>https://onlinelibrary.wiley.com/doi/abs/10.1002/syn.20647</ref>, which may be partially responsible for its dissociative and hallucinogenic effects.

However, the role of these interactions and how they result in a [[hallucinogenic]] experience continues to remain the subject of ongoing scientific inquiry.

@@ Line 10: / Line 10: @@
 ==Pharmacology==
-Salvinorin A is a potent [[Opioid#Kappa_.28.CE.BA.29|κ-opioid]] receptor [[agonist]]. It does not have any effect on the 5-HT<sub>2A</sub> receptor, the receptor targeted by most [[psychedelic]] drugs, nor does it function as an NMDA receptor antagonist as most dissociatives do. Its unique structure lacks features commonly associated with opioid ligand binding, namely it doesn't contain a quaternary carbon atom linked to a tertiary amine group by two other carbon atoms. Unlike traditional opioid agonists, salvinorin A targets the [[Opioid#Kappa_.28.CE.BA.29|κ-opioid]] receptor rather than the [[Opioid#Mu_.28.CE.BC.29|μ-opioid]] receptor. Salvinorin A is currently being researched in relation to its properties as an anti-addiction drug, and several analogs with improved pharmacokinetic profiles have been shown to have anti-addictive effects as well.<ref>http://www.ncbi.nlm.nih.gov/pubmed/24484985</ref>
+Salvinorin A is a potent [[Opioid#Kappa_.28.CE.BA.29|κ-opioid]] receptor [[agonist]]. It does not have any effect on the 5-HT<sub>2A</sub> receptor, the receptor targeted by most [[psychedelic]] drugs, nor does it function as an NMDA receptor antagonist as most dissociatives do. Its unique structure lacks features commonly associated with opioid ligand binding, namely it doesn't contain a quaternary carbon atom linked to a tertiary amine group by two other carbon atoms. Unlike traditional opioid agonists, salvinorin A targets the [[Opioid#Kappa_.28.CE.BA.29|κ-opioid]] receptor rather than the [[Opioid#Mu_.28.CE.BC.29|μ-opioid]] receptor. Salvinorin A is currently being researched in relation to its properties as an anti-addiction drug, and several analogs with improved pharmacokinetic profiles have been shown to have anti-addictive effects as well.<ref>http://www.ncbi.nlm.nih.gov/pubmed/24484985</ref> Salvinorin A also acts as a potent agonist at [[dopamine|D<sub>2</sub>]] receptors<ref>https://onlinelibrary.wiley.com/doi/abs/10.1002/syn.20647</ref>, which may be partially responsible for its dissociative and hallucinogenic effects.
 However, the role of these interactions and how they result in a [[hallucinogenic]] experience continues to remain the subject of ongoing scientific inquiry.